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Hypertension is the single largest global contributor to
disability-adjusted life years lost [1]. The majority of the
population aged over 60 years have hypertension [2], and it
has been suggested that they may be at increased risk from
the effects of COVID-19. Despite this, and perhaps due to
its ubiquity in the older population, current UK Government
guidance does not identify people with hypertension as ʻat
risk’ [3], however, other bodies such as the British Heart
Foundation and the Health Service Executive in Ireland do
[4, 5]. This article seeks to summarise and interpret the
current evidence for and against an increase in COVID-19
risk and severity for those with raised blood pressure, and
discusses the implications for the choice of anti-
hypertensive treatment.
Early small case series did not indicate an excess of
hypertension in people admitted to hospital with COVID-19
[6]. The Novel Coronavirus Pneumonia Emergency
Response Epidemiology Team published a large case series
from China; they found an overall case fatality rate of 2.3%
(1023 of 44,672 confirmed cases), which increased to 6.0%
for people with hypertension [7]. These data were reported
without adjustment for age. Both COVID-19 case fatality
rates and hypertension prevalence increase with age,
reaching 8.0% and over 50% respectively for the 70–79
year age group [2]. New emerging evidence from the largest
epidemiological study to date, examining over 17 million
health records in England suggests that hypertension or a
recorded blood pressure ≥140/90 mmHg taken together are
not associated with COVID-19 in-hospital mortality after
full adjustment: Hazard Ratio (HR) 0.95, (95% confidence
interval (CI) 0.89–1.01). In sensitivity analyses, diagnosed
hypertension alone was associated with slightly increased
risk (HR 1.07, 95% CI 1.00–1.15) which might reflect
residual confounding due to the strong age-related asso-
ciation [8].
Several other small case series that examine hypertension
prevalence with and without severe COVID-19 have
appeared in the literature [9]. In March 2020, a study-level
meta-analysis of 2552 confirmed COVID-19 patients
reported a pooled odds ratio (OR) of 2.49 (CI: 1.98–3.12;
11 studies) for severe disease in the presence of hyperten-
sion, with low heterogeneity between studies (I2= 24%).
The OR for death was similar and weak evidence from
meta-regression suggested that hypertension might be a
clinical predictor of COVID-19 severity in people aged over
60 [10]. Likewise, a retrospective cohort analysis of 191
patients treated in hospital in China (not included in the
meta-analysis) confirmed apparent high mortality in
patients presenting with hypertension: 48% versus 23% of
survivors [11].
Similar findings were reported with previous coronavirus
infections, such as severe acute respiratory syndrome and
Middle East Respiratory Syndrome [12, 13]. The mechan-
ism by which hypertension leads to increased risk from
COVID-19 is undoubtedly complex and may well relate to
underlying co-morbidity. The prognosis for people with
hypertension is markedly worse when COVID-19 infection
is complicated by myocardial injury and in the presence of
cardiovascular disease [8, 14]. End organ damage and car-
diovascular events are associated with poorer control of
high blood pressure, and mean blood pressure rises with age
[15, 16]. It seems plausible, therefore, that older age, poorer
blood pressure control and cardiovascular disease can
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explain the observed associations between age, hyperten-
sion and severity of COVID-19 infection.
Are anti-hypertensive medications a risk for
severity of COVID-19?
The viral structural spike (S) protein binds to the
angiotensin-converting enzyme 2 (ACE2) receptor to gain
entry to cells; this has led to suggestions that use of ACE
inhibitors and angiotensin II type-I receptor blockers
(ARBs) may be implicated in poorer outcomes with
COVID-19 [17, 18]. Whilst gaining much publicity, with
attendant worry for patients and clinicians, this theory has
been debated and ACE inhibitor and ARB treatment has
also been associated with improved outcomes in some
reports [19, 20]. Polymorphism in expression of the ACE2
receptor gene in association with hypertension and excess
cardiovascular risk in ethnic minority groups has also been
suggested as a partial explanation for observed excess
mortality from COVID-19 in these populations [21, 22].
The National Institute for Health and Care Excellence are
currently undertaking a rapid review of this topic [23].
Recent observational studies of confirmed COVID-19
patients have increased confidence that these drugs are not
harmful: a case-control study of 6272 COVID-19 patients
in Lombardy, Italy, matched to 30,759 controls, confirmed
higher use of ACE inhibitors and ARBs in patients than
controls, but after adjustment for greater prevalence of
underlying cardiovascular disease, there was no evidence
that ACE inhibitors (OR 0.96; 95% CI 0.87–1.07) or
ARBs (OR 0.95; 95% CI 0.86–1.05) were associated with
different risks of COVID-19 [24]. Two large retrospective
cohort studies have also been published; one found no
association between ACE inhibitor or ARB use and a
positive coronavirus test in 18,472 people from
Ohio and Florida (weighted OR 0.97; 95% CI 0.81–1.15),
whist another study of 12,594 electronic health records
from New York, found no association between any
anti-hypertensive medication (ACE inhibitors, ARBs,
beta-blockers, calcium-channel blockers, or thiazide
diuretics) and increased likelihood of either a positive
coronavirus test or an increased risk of severe COVID-19
illness [25, 26].
It is important to recognise that, to date, no randomised
trial evidence exists to demonstrate either benefits or risks of
continuing ACE inhibitors or ARBs on the incidence or
outcomes of COVID-19. It must also be acknowledged that
these observational data carry risks of residual confounding
[27]. One retrospective cohort study found a positive asso-
ciation between ACE inhibitor or ARB use and admission to
hospital (OR 1.93; 95% CI 1.38–2.71) or intensive care
(OR 1.64; 95% CI 1.07–2.51) in small subgroup analyses
(N= 421 and 161, respectively) [26]. These secondary
outcomes are rightly viewed with caution due to the
potential for residual confounding by co-morbidity and also
imprecision (as evidenced by wide confidence intervals) due
to small sample sizes [28]. Nevertheless, these studies taken
together convey a consistent message of absence of harm
associated with anti-hypertensive medications during infec-
tion with coronavirus, and clinical equipoise should there-
fore apply. Whilst these drugs appear increasingly unlikely
to worsen COVID-19 severity, the consequences of poor
blood pressure control, under normal circumstances, are well
documented [16]. Consequently, the British and Irish
Hypertension Society (BIHS), and our European and Inter-
national partner societies, have issued clear position state-
ments advising against cessation of anti-hypertensive
therapy on the grounds of concern over risks with COVID-
19 (available at: https://bihsoc.org/bihs-statement-on-acei-a
rb-and-covid19/) [29]. Current evidence does not support
published opinions that doctors may consider stopping
treatment with ACE inhibitors and ARBs in well-controlled
patients with mild (Stage 1) hypertension and coronavirus
infection [30]. The unintended consequences of discontinu-
ing effective treatments for hypertension, without a suitable
replacement titrated against appropriate blood pressure
measurements and under direct medical supervision,
could put patients at increased cardiovascular risk. In addi-
tion, managing such titration at a time when primary care is
prioritising acute illness over routine contacts
(including surgery blood pressure checks), makes the pro-
posed strategy impractical and risks further diluting access
to care.
So, what can we say to hypertensive patients
who may be anxious about taking anti-
hypertensive medication and about their
risks from infection during the COVID-19
pandemic?
The evidence base remains incomplete, so strong recom-
mendations are difficult. However, people with complica-
tions of hypertension, such as ischaemic heart disease, are
already regarded as being at high risk from COVID-19. It
seems reasonable to advise those with poorly controlled
hypertension (i.e. blood pressure above guideline targets),
particularly if prolonged, to also consider themselves to be
at elevated risk, and, therefore, to follow appropriate social
distancing advice [3]. For younger individuals with hyper-
tension, there is an association of obesity with COVID-19
severity among Western populations [2, 8, 31, 32]. Gen-
erally, for people with good control of blood pressure, risks
of undiagnosed cardiovascular disease are low, and they
could therefore be reassured. All hypertensive patients
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should be strongly reassured that continuing their current
medications is both safe and desirable.
We should support all our hypertensive patients in con-
tinuing to strive for, and maintain, good blood pressure
control by continuing to take their medications as pre-
scribed, and by endeavouring to follow and maintain sen-
sible lifestyle choices, including regular exercise [3].
Large numbers of people are being affected by COVID-
19 with potentially profound consequences, however, their
continued surveillance will also provide further data that
will help us to understand the true risk from elevated blood
pressure, its treatment and co-morbidities, on outcomes of
the disease. Careful and continuous research is vital for an
understanding of the mechanisms underlying any additional
risk from hypertension with COVID-19, and to determine
the best and safest ways to treat those with severe mani-
festations of disease. Our patients are best served when their
treatment is based on available evidence rather than spec-
ulation, and the growing body of evidence suggests that
continuation of ACE inhibitors and ARBs during the cur-
rent COVID-19 pandemic is safe.
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